华熙生物董事长赵燕在《钱道》访谈中表示："女人有'三怕'，一个是怕老，一个是怕丑，一个是怕 死。随着生命科学的发展，这三个方面都是能够去有效地控制的。" 谈及衰老，她表示"每个人对衰老都有担忧，但是我不害怕"。她认为真正的衰老从细胞层面开始，"由 于工作的压力，或者生活中的不顺心，这些都会影响细胞生存的环境，改变细胞信息的传递，导致混 乱。那一刻，你会觉得'哪哪都不对劲'，这其实就是衰老的开始。" 关于医美，她表示："医美说到底，它让你重拾自信，尤其对于女性，你就看到了自己不是说随着时间 的推移，我慢慢地老去，我能够掌控自己，能够很优雅地去变老。" 由@新浪财经、微博联合打造，@微博财经 #达芬奇live# 出品的对话栏目#钱道# 第一期，邀请华熙生 物董事长赵燕，与英才元投资管理有限公司董事长@宋立新 在15分钟精华对话中，坦诚分享如何识别 组织衰老、推动认知对齐、重建执行逻辑。#透过财经看世界# 新浪声明：所有会议实录均为现场速记整理，未经演讲者审阅，新浪网登载此文出于传递更多信息之目 的，并不意味着赞同其观点或证实其描述。 专题：《钱道》：对话上市公司掌门人 专题：《钱道》：对话上市公司掌门人 华熙生物 ...

在对话中，谈及衰老的话题，华熙生物董事长赵燕坦言，"每个人对衰老都有担忧，但是我不害怕。" 赵燕表示，大家都认为衰老是一个自然过程，但是在生命科学领域来说，衰老是能够被主动干预和控制 的过程。容颜的衰老它只是一个表面，要更关注"生命的延长"，怎么样有质量地活得长。 她提到，女人有"三怕"：怕老、怕丑、怕死。随着生命科学的发展，这三个方面都是能够去有效地控制 的。华熙生物的使命，是让每个生命都是鲜活的，所以要提高生命质量，让人活得长。"医美说到底， 是让人重拾自信，尤其对于女性，能够很优雅地变老，更多的是一个心理上的慰藉。" 由@新浪财经、微博联合打造，@微博财经 #达芬奇live# 出品的对话栏目#钱道# 第一期，邀请华熙生 物董事长赵燕，与英才元投资管理有限公司董事长@宋立新 在15分钟精华对话中，坦诚分享如何识别 组织衰老、推动认知对齐、重建执行逻辑。#透过财经看世界# 新浪声明：所有会议实录均为现场速记整理，未经演讲者审阅，新浪网登载此文出于传递更多信息之目 的，并不意味着赞同其观点或证实其描述。 专题：《钱道》：对话上市公司掌门人 责任编辑：李昂 专题：《钱道》：对话上市公司掌门人 责任编辑：李昂 在 ...

Market Overview - The A-share market saw a majority of indices decline today, with the Shanghai Composite Index down by 0.64% closing at 4075.92 points, the Shenzhen Component Index down by 1.44% at 13952.71 points, the Sci-Tech 50 down by 1.44% at 1432.52 points, and the ChiNext Index down by 1.55% at 3260.28 points [1][10] - Overall, there were 1616 stocks that rose and 3715 stocks that fell, with a total market turnover of 21762 billion, a decrease of 3048 billion compared to the previous trading day [1] Industry Performance - Among the Shenwan first-level industries, the leading sectors included Beauty Care, Banking, Food & Beverage, Retail, and Textile & Apparel, with respective gains of 3.21%, 1.57%, 1.31%, 0.90%, and 0.74% [1] - Conversely, the sectors that experienced the largest declines were Non-ferrous Metals, Electric Equipment, Communication, Coal, and Steel, with respective losses of 4.57%, 3.41%, 2.39%, 2.22%, and 2.15% [1] Concept Sectors - The top-performing concept sectors today included Cross-Strait Integration, Selected Banks, Travel & Outing, and others, while sectors like Power Equipment Selection and BC Battery experienced pullbacks [2][12]

Group 1 - The core viewpoint of the article highlights that Han Commercial Group has experienced a consecutive two-day trading limit increase, indicating strong market interest and performance [1] - The stock reached a trading limit at 9:59 AM with a transaction volume of 416 million yuan and a turnover rate of 12.75% [1] - Recent favorable policies related to the infant and child sector have contributed to the market's attention on Han Commercial Group, which is expanding into the assisted reproductive field and holds licenses for reproductive hospitals and stem cell research [1] Group 2 - The company has made breakthroughs in medical aesthetic materials, aligning its business with the growing market interest in healthcare consumption [1] - The convergence of multiple concepts within the company's operations has sparked increased market focus and investor interest [1]

Investment Logic - The company is leveraging its expertise in cardiovascular devices to enter the medical aesthetics market, with a product lineup that includes facial rejuvenation injections, water light injections, PDRN, and Thermage, aiming for rapid profit growth [1] - The company employs a "rural encircling urban" strategy for channel distribution, achieving over 80% coverage in large chain medical aesthetic institutions, with plans to further penetrate second and third-tier cities [1] Product Development and Market Strategy - The facial rejuvenation injection uses materials sourced from heart stents and has quickly gained market traction, generating a tax-inclusive revenue of 100 million yuan from early August to the end of October, with expectations to rank among the top three brands in the industry [2] - PDRN is anticipated to receive domestic approval by Q1 2026, positioning the company to be the first to market with a compliant PDRN injection product in a currently underserved market [2] Financial Performance and Projections - The company's traditional business is stabilizing, while the medical aesthetics, neurostimulation, and innovative pharmaceuticals are forming new growth drivers. Revenue projections for 2025, 2026, and 2027 are 6.457 billion, 7.792 billion, and 9.243 billion yuan, respectively, with year-on-year growth rates of +5.79%, +20.68%, and +18.62% [3] - The net profit attributable to shareholders is forecasted to reach 1.048 billion, 1.285 billion, and 1.531 billion yuan for the same years, reflecting significant growth of +324.34%, +22.64%, and +19.13% [3] - The company is assigned a target price of 21 yuan based on a 30x valuation for 2026, with an initial "buy" rating [3]

Core Insights - The recognition of Ms. Miao Guili as "CFO of the Year" reflects the effective implementation of the dual-driven strategy of "innovative drugs + medical aesthetics" at Four Rings Pharmaceutical during a critical transformation period [1] - The management team's understanding of industry trends is crucial for sustainable development and strategic adjustments in response to market uncertainties [1] Innovative Drug Business - The Chinese innovative drug industry is entering a golden period of high-quality development by 2025, supported by new policies and market dynamics [3] - In 2023, 69 innovative drugs were approved for market entry in China, marking a historical high, with oncology and metabolic diseases as key research areas [3] - Four Rings Pharmaceutical has successfully launched three drugs in its innovative drug segment, focusing on oncology and metabolic diseases, and is advancing its pipeline with significant products [4][5] Medical Aesthetics Business - The medical aesthetics sector of Four Rings Pharmaceutical is experiencing high-quality growth amid industry regulation, with new pricing guidelines reshaping the market landscape [7] - The Chinese medical aesthetics market has surpassed 300 billion yuan, with a projected compound annual growth rate exceeding 20% over the next five years [8] - Four Rings has established a competitive advantage in the medical aesthetics field with over 30 products in development, including various injectables and skin management devices [9] Market Position and Future Outlook - The company is gaining attention from brokerage firms, with many believing that it is undervalued and has significant potential for valuation recovery [11] - The dual-driven strategy in innovative drugs and medical aesthetics is expected to enhance the company's market value as it continues to realize its R&D achievements and expand globally [11]

Core Viewpoint - The company is actively pursuing a strategic transformation and development in the dermatology sector, leveraging its expertise in biodegradable biomaterials and the promising outlook of the consumer healthcare market [1] Group 1: Strategic Focus - The company's strategic core is to utilize its technological advantages in biodegradable materials, such as PLLA, to extend its successful experience from the cardiovascular interventional field into dermatology [1] - The company aims to gradually expand its product portfolio to include hyaluronic acid and botulinum toxin among other diverse offerings [1] Group 2: Product Development - The company has successfully launched its self-developed polylactic acid facial filler (童颜针), injectable sodium hyaluronate solution (水光针), and cross-linked sodium hyaluronate gel, marking the initial formation of its dermatology injection product matrix [1] - Several products under development are progressing as planned, with the injectable sodium hyaluronate composite solution and Thermage having completed the submission of their materials [1]

Core Viewpoint - The company has a strong order backlog and is actively advancing its JH389 project in the medical aesthetics sector, focusing on weight loss and blood sugar control [1] Group 1: Company Developments - The JH389 project has submitted a patent application in Europe during Q3 2025 [1] - Ongoing safety trials for the JH389 project in Europe are progressing smoothly [1] - The company and its partners are concentrating on production, formulation design, and scientific research related to the JH389 project [1] Group 2: Commercialization Efforts - The company is actively promoting the commercialization of the JH389 project [1]

Core Insights - The establishment of the medical beauty and cosmetics division by Pro Pharmaceutical (普洛药业) on November 4, 2024, aims to enhance quality of life with a focus on product and client development in this sector [2]. Group 1: Business Development - The medical beauty and cosmetics raw materials business is a key development direction for the company, currently in the phase of developing new products and clients [2]. - The company anticipates that the market size for this business segment will experience rapid growth in the coming years [2].

Group 1 - The company has expanded its business scope to include wholesale and retail of cosmetics, indicating a strategic move into the beauty market [1] - The company will continue to monitor market demand trends and enhance its ability to provide value-added services in relevant business areas [1]